EMA Recommends Granting a Marketing Authorisation for Vimseltinib By Ogkologos - September 5, 2025 165 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults with symptomatic tenosynovial giant cell tumour Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Abnormal Collagen May Be Weak Spot for Pancreatic Cancer August 22, 2022 Breast Cancer Patient Fights To Have Mastectomy During COVID-19 Restrictions And... May 12, 2020 Mapping Cancer Genomic Evolution Offers Insights into Tumor Development March 6, 2020 2020 round-up: Our biggest cancer stories of the year December 20, 2020 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΤΟΥ ΜΑΣΤΟΥ Promising Signal of Efficacy for Adjuvant Nivolumab in Patients with Completely... Removing senescent immune cells could be the key to preventing some... Outcome of EMA Assessment on Use of Lutetium (177Lu) in Treatment...
